{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T03:40:43Z","timestamp":1782531643290,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,3,23]],"date-time":"2018-03-23T00:00:00Z","timestamp":1521763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This study was funded by the Janssen Prevention Center"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Epidemiol"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s10654-018-0381-0","type":"journal-article","created":{"date-parts":[[2018,3,23]],"date-time":"2018-03-23T03:25:25Z","timestamp":1521775525000},"page":"635-644","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["The importance of endpoint selection: How effective does a drug need to be for success in a clinical trial of a possible Alzheimer\u2019s disease treatment?"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2345-5249","authenticated-orcid":false,"given":"Stephanie","family":"Evans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"McRae-McKee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Mei","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoforos","family":"Hadjichrysanthou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"De Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,23]]},"reference":[{"key":"381_CR1","unstructured":"Alzheimer\u2019s Disease International. World Alzheimer\u2019s Report. Alzheimer\u2019s Disease International. 2016. \n                    https:\/\/www.alz.co.uk\/research\/world-report-2016\n                    \n                  . Accessed 30 Mar 2017."},{"key":"381_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2217\/nmt.11.11","volume":"1","author":"MC Biagioni","year":"2011","unstructured":"Biagioni MC, Galvin JE. Using biomarkers to improve detection of Alzheimer\u2019s disease. Neurodegener Dis Manag. 2011;1:127\u201339.","journal-title":"Neurodegener Dis Manag."},{"key":"381_CR3","unstructured":"Patel V. Deaths registered in England and Wales (series DR): 2015\u2014Office for National Statistics. Office for National Statistics. 2016. \n                    https:\/\/www.ons.gov.uk\/releases\/deathsregisteredinenglandandwalesseriesdr2013\n                    \n                  . Accessed 28 Apr 2017."},{"key":"381_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/joim.12191","volume":"275","author":"LS Schneider","year":"2014","unstructured":"Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, et al. Clinical trials and late-stage drug development for Alzheimer\u2019s disease: an appraisal from 1984 to 2014. J Intern Med. 2014;275:251\u201383.","journal-title":"J Intern Med"},{"key":"381_CR5","unstructured":"EMA. European Medicines Agency Committee for Medicinal Products for Human Use. Draft guideline on the clinical investigation of medicines for the treatment of Alzheimer\u2019s disease and other dementias. 2016. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2016\/02\/WC500200830.pdf\n                    \n                  ."},{"key":"381_CR6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3233\/JAD-2008-15213","volume":"15","author":"RE Becker","year":"2008","unstructured":"Becker RE, Greig NH, Giacobini E. Why do so many drugs for Alzheimer\u2019s disease fail in development? Time for new methods and new practices? J Alzheimers Dis. 2008;15:303\u201325.","journal-title":"J Alzheimers Dis"},{"key":"381_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/WNN.0b013e318190cf75","volume":"21","author":"DS Knopman","year":"2008","unstructured":"Knopman DS. Clinical trial design issues in mild to moderate Alzheimer disease. Cogn Behav Neurol Off J Soc Behav Cogn Neurol. 2008;21:197\u2013201.","journal-title":"Cogn Behav Neurol Off J Soc Behav Cogn Neurol."},{"key":"381_CR8","unstructured":"FDA. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Draft guidance for industry\u2014Alzheimer\u2019s disease: developing drugs for the treatment of early stage disease. 2013. \n                    http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM338287.pdf\n                    \n                  ."},{"key":"381_CR9","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","volume":"141","author":"WG Rosen","year":"1984","unstructured":"Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer\u2019s disease. Am J Psychiatry. 1984;141:1356\u201364.","journal-title":"Am J Psychiatry"},{"key":"381_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s11682-012-9166-3","author":"J Skinner","year":"2012","unstructured":"Skinner J, Carvalho JO, Potter GG, Thames A, Zelinski E, Crane PK, et al. The Alzheimer\u2019s disease assessment scale-cognitive-plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI. Brain Imaging Behav. 2012. \n                    https:\/\/doi.org\/10.1007\/s11682-012-9166-3\n                    \n                  .","journal-title":"Brain Imaging Behav"},{"key":"381_CR11","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1136\/jnnp.2009.204008","volume":"81","author":"SJ Cano","year":"2010","unstructured":"Cano SJ, Posner HB, Moline ML, Hurt SW, Swartz J, Hsu T, et al. The ADAS-cog in Alzheimer\u2019s disease clinical trials: psychometric evaluation of the sum and its parts. J Neurol Neurosurg Psychiatry. 2010;81:1363\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"381_CR12","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jalz.2012.08.005","volume":"9","author":"J Hobart","year":"2013","unstructured":"Hobart J, Cano S, Posner H, Selnes O, Stern Y, Thomas R, et al. Putting the Alzheimer\u2019s cognitive test to the test I: traditional psychometric methods. Alzheimers Dement. 2013;9:S4\u20139.","journal-title":"Alzheimers Dement"},{"key":"381_CR13","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/00002093-200110000-00003","volume":"15","author":"PM Doraiswamy","year":"2001","unstructured":"Doraiswamy PM, Kaiser L, Bieber F, Garman RL. The Alzheimer\u2019s disease assessment scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer\u2019s disease. Alzheimer Dis Assoc Disord. 2001;15:174\u201383.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"381_CR14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","volume":"74","author":"RC Petersen","year":"2010","unstructured":"Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer\u2019s disease neuroimaging initiative (ADNI). Neurology. 2010;74:201\u20139.","journal-title":"Neurology."},{"key":"381_CR15","unstructured":"Bloom HS. The Core Analytics of Randomized Experiments for Social Research. MDRC Working Papers on Research Methodology. MDRC; 2006. \n                    https:\/\/eric.ed.gov\/?id=ED493363\n                    \n                  . Accessed 26 Apr 2017."},{"key":"381_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13195-015-0151-0","volume":"7","author":"N Verma","year":"2015","unstructured":"Verma N, Beretvas SN, Pascual B, Masdeu JC, Markey MK. New scoring methodology improves the sensitivity of the Alzheimer\u2019s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials. Alzheimers Res Ther. 2015;7:64.","journal-title":"Alzheimers Res Ther"},{"key":"381_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13195-016-0170-5","volume":"8","author":"J Podhorna","year":"2016","unstructured":"Podhorna J, Krahnke T, Shear M, Harrison J. Alzheimer\u2019s Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer\u2019s disease: change over time and the effect of enrichment strategies. Alzheimers Res Ther. 2016;8:8.","journal-title":"Alzheimers Res Ther"},{"key":"381_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189\u201398.","journal-title":"J Psychiatr Res"},{"key":"381_CR19","unstructured":"Mungas D. In-office mental status testing: a practical guide. Geriatrics 1991;46:54\u201358, 63, 66."},{"key":"381_CR20","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695\u20139.","journal-title":"J Am Geriatr Soc"},{"key":"381_CR21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","volume":"74","author":"RC Petersen","year":"2010","unstructured":"Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74:201\u20139.","journal-title":"Neurology"},{"key":"381_CR22","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/jmri.21049","volume":"27","author":"CR Jack","year":"2008","unstructured":"Jack CR, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI): MRI Methods. J Magn Reson Imaging JMRI. 2008;27:685\u201391.","journal-title":"J Magn Reson Imaging JMRI"},{"key":"381_CR23","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.jalz.2015.05.002","volume":"11","author":"CR Jack Jr","year":"2015","unstructured":"Jack CR Jr, Barnes J, Bernstein MA, Borowski BJ, Brewer J, Clegg S, et al. Magnetic resonance imaging in Alzheimer\u2019s disease neuroimaging initiative 2. Alzheimers Dement. 2015;11:740\u201356.","journal-title":"Alzheimers Dement"},{"key":"381_CR24","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1212\/WNL.55.4.484","volume":"55","author":"CR Jack","year":"2000","unstructured":"Jack CR, Petersen RC, Xu Y, O\u2019Brien PC, Smith GE, Ivnik RJ, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology. 2000;55:484\u201390.","journal-title":"Neurology"},{"key":"381_CR25","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1212\/WNL.52.7.1397","volume":"52","author":"CR Jack","year":"1999","unstructured":"Jack CR, Petersen RC, Xu YC, O\u2019Brien PC, Smith GE, Ivnik RJ, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52:1397\u2013403.","journal-title":"Neurology"},{"key":"381_CR26","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1212\/01.WNL.0000042480.86872.03","volume":"60","author":"CR Jack","year":"2003","unstructured":"Jack CR, Slomkowski M, Gracon S, Hoover TM, Felmlee JP, Stewart K, et al. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology. 2003;60:253\u201360.","journal-title":"Neurology"},{"key":"381_CR27","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1148\/radiol.2482070938","volume":"248","author":"JD Sluimer","year":"2008","unstructured":"Sluimer JD, van der Flier WM, Karas GB, Fox NC, Scheltens P, Barkhof F, et al. Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients. Radiology. 2008;248:590\u20138.","journal-title":"Radiology"},{"key":"381_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/alzrt25","volume":"2","author":"RS Doody","year":"2010","unstructured":"Doody RS, Pavlik V, Massman P, Rountree S, Darby E, Chan W. Predicting progression of Alzheimer\u2019s disease. Alzheimers Res Ther. 2010;2:2.","journal-title":"Alzheimers Res Ther"},{"key":"381_CR29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/geronj\/37.3.323","volume":"37","author":"RI Pfeffer","year":"1982","unstructured":"Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37:323\u20139.","journal-title":"J Gerontol"},{"key":"381_CR30","unstructured":"Mayo A. Use of the Functional Activities Questionnaire in Older Adults with Dementia | ConsultGeri Assessment Tool. 2015. \n                    https:\/\/consultgeri.org\/try-this\/dementia\/issue-d13\n                    \n                  . Accessed 27 Jul 2017."},{"key":"381_CR31","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1136\/jnnp-2015-312383","volume":"87","author":"J Wang","year":"2016","unstructured":"Wang J, Logovinsky V, Hendrix SB, Stanworth SH, Perdomo C, Xu L, et al. ADCOMS: a composite clinical outcome for prodromal Alzheimer\u2019s disease trials. J Neurol Neurosurg Psychiatry. 2016;87:993\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"381_CR32","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2014.803","volume":"71","author":"MC Donohue","year":"2014","unstructured":"Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014;71:961\u201370.","journal-title":"JAMA Neurol"},{"key":"381_CR33","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jalz.2014.03.008","volume":"11","author":"Y Huang","year":"2015","unstructured":"Huang Y, Ito K, Billing CB, Anziano RJ. Alzheimer\u2019s Disease Neuroimaging Initiative. Development of a straightforward and sensitive scale for MCI and early AD clinical trials. Alzheimers Dement J Alzheimers Assoc. 2015;11:404\u201314.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"381_CR34","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.neurobiolaging.2012.03.006","volume":"34","author":"JD Grill","year":"2013","unstructured":"Grill JD, Di L, Lu PH, Lee C, Ringman J, Apostolova LG, et al. Estimating sample sizes for pre-dementia Alzheimer\u2019s trials based on the Alzheimer\u2019s Disease Neuroimaging Initiative. Neurobiol Aging. 2013;34:62\u201372.","journal-title":"Neurobiol Aging"},{"issue":"Suppl 3","key":"381_CR35","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3233\/JAD-2011-0062","volume":"26","author":"MC Ard","year":"2011","unstructured":"Ard MC, Edland SD. Power calculations for clinical trials in Alzheimer\u2019s disease. J Alzheimers Dis JAD. 2011;26(Suppl 3):369\u201377.","journal-title":"J Alzheimers Dis JAD"},{"key":"381_CR36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12874-016-0144-0","volume":"16","author":"EL Ashbeck","year":"2016","unstructured":"Ashbeck EL, Bell ML. Single time point comparisons in longitudinal randomized controlled trials: power and bias in the presence of missing data. BMC Med Res Methodol. 2016;16:43.","journal-title":"BMC Med Res Methodol"},{"key":"381_CR37","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s12603-012-0047-7","volume":"16","author":"MC Donohue","year":"2012","unstructured":"Donohue MC, Aisen PS. Mixed model of repeated measures versus slope models in Alzheimer\u2019s disease clinical trials. J Nutr Health Aging. 2012;16:360\u20134.","journal-title":"J Nutr Health Aging"},{"key":"381_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach. Acta Neuropathol (Berl). 2012;123:1\u201311.","journal-title":"Acta Neuropathol (Berl)"},{"key":"381_CR39","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","volume":"385","author":"T Ngandu","year":"2015","unstructured":"Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, Antikainen R, Backman L, Hanninen T, Jula A, Laatikainen T, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet Lond Engl. 2015;385:2255\u201363.","journal-title":"Lancet Lond. Engl"}],"container-title":["European Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10654-018-0381-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10654-018-0381-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10654-018-0381-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T20:08:05Z","timestamp":1553285285000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10654-018-0381-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,23]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["381"],"URL":"https:\/\/doi.org\/10.1007\/s10654-018-0381-0","relation":{},"ISSN":["0393-2990","1573-7284"],"issn-type":[{"value":"0393-2990","type":"print"},{"value":"1573-7284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,23]]},"assertion":[{"value":"16 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"R.M.A. is a non-executive board member of GlaxoSmithKline (GSK). GSK played no part in this research, its funding or the preparation of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Obtained by ADNI. Not applicable to this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Obtained from ADNI.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}